Product
Autoantibody Reductive Therapy
1 clinical trial
2 indications
Indication
Idiopathic Pulmonary FibrosisIndication
Acute Fatal FormClinical trial
Study of Therapeutic Plasma Exchange, Rituximab and Intravenous Immunoglobulin for Acute Exacerbations of Idiopathic Pulmonary Fibrosis (STRIVE-IPF)Status: Recruiting, Estimated PCD: 2024-08-01